期刊文献+

Anti-Hepatitis B Virus Drugs in Clinical and Preclinical Development

Anti-Hepatitis B Virus Drugs in Clinical and Preclinical Development
下载PDF
导出
摘要 Up to date, there are two types of drugs approved to treat hepatitis B: interferons and nucleos (t) ide analogues. However, the therapies are limited in the clinical context because of the negative side effects of interferon-or and the development of substantial viral resistance to nucleos (t) idic inhibitors. Therefore, new drugs with novel structures and mechanisms are needed. In this article, the drugs approved by FDA or the European Commission for treating chronic hepatitis B virus infection, as well as those under clinical trials, and several compounds in preclinical studies are reviewed. Additionally, some potential targets and strategies to combat chronic hepatitis B virus infection are discussed. Up to date, there are two types of drugs approved to treat hepatitis B: interferons and nucleos (t) ide analogues. However, the therapies are limited in the clinical context because of the negative side effects of interferon-α and the development of substantial viral resistance to nucleos (t) idic inhibitors. Therefore, new drugs with novel structures and mechanisms are needed. In this article, the drugs approved by FDA or the European Commission for treating chronic hepatitis B virus infection, as well as those under clinical trials, and several compounds in preclinical studies are reviewed. Additionally, some potential targets and strategies to combat chronic hepatitis B virus infection are discussed.
出处 《Virologica Sinica》 SCIE CAS CSCD 2008年第2期137-145,共9页 中国病毒学(英文版)
关键词 Anti-HBV drugs Immunomodulatory agents HBV 抗原体 甲肝 临床分析 治疗方法
  • 相关文献

参考文献41

  • 1[1]Announces of cubo pharmaceuticals:http://findarticles.com/p/articles/mi_m0EIN/is_2005_August_9/ ai_n1487-3142
  • 2[2]Biron C A.1998.Role of early cytokines,including alpha and beta interferons (IFN-alpha/beta),in innate and adaptive immune responses to viral infections.Semin Immunol,10:383-390.
  • 3[3]Bowden S,Jackson K,Littlejohn M,et al.2004.Quantification of HBV Covalently Closed Circular DNA from Liver Tissue by Real-Time PCR.In:Hepatitis B and D protocols (Lau J Y N,Hamatake R,eds.),Volume 1:Detection,Genotypes,and Characterization.Robert K.Hamatake,Johnson Y.N.Lau:HumanaPress,41-51.ISBN:1-59259-669-X Series:Methods in Molecular Medicine.
  • 4[4]Cooksley W G,Piratvisuth T,Lee S D,et al.2003.Peginterferon a-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B,J Viral Hepat,10:298-305.
  • 5[5]De Clercq E.2003.Clinical potential of the acyclic nucleoside phosphonates cidofovir,adefovir,and tenofovir in treatment of DNA virus and retrovirus infections.Clin Microbiol Rev,16:569-596.
  • 6[6]Delaney W E 4th,Edwards R,Colledge D,et al.2002.Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.Antimicrob Agents Chemother,46:3057-3060.
  • 7[7]Deres K,Schr(o)der C H,Paessens A,et al.2005.Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.Science,299:893-896.
  • 8[8]Digestive Disease Week,May 19-24,2007,Washington DC.http://www.hivandhepatitis.com/ 2007icr/ddw/ docs/ 052507 b.html
  • 9[9]Enzo therapeutics:http://www.enzobio.com/ therapeutics/ product_pipeline.asp.
  • 10[10]Hepatitis B fact sheet WHO/204 Geneva:World Health Organization.2000.http:/www.who.int/infs/en/ fact204.html (21 December 2005,date last accessed).

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部